🇺🇸 FDA
Pipeline program

ARQ-151 0.3% cream

ARQ-151-302

Phase 3 small_molecule completed

Quick answer

ARQ-151 0.3% cream for Chronic Plaque Psoriasis is a Phase 3 program (small_molecule) at Arcutis Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcutis Biotherapeutics
Indication
Chronic Plaque Psoriasis
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials